Evidence map›Paper›PMID 36266066›Full record

ArticleInternal medicine journal2022

Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.

Xavier Brennan, Barbara Withers, Andrew Jabbour, Sam Milliken, Eugene Kotlyar, Keith Fay, David Ma, Kavitha Muthiah, Nada Hamad, Anthony Dodds and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Treatment of amyloidosis: present and future.European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Xavier BrennanCardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.ORCID 0000-0002-0306-3926
Barbara WithersDepartment of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Andrew JabbourCardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Sam MillikenUniversity of New South Wales, Sydney, New South Wales, Australia.
Eugene KotlyarCardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Keith FayDepartment of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
David MaDepartment of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Kavitha MuthiahCardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Nada HamadUniversity of New South Wales, Sydney, New South Wales, Australia.
Anthony DoddsDepartment of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Nikki BartThe Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia.
Anne KeoghCardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Chris HaywardCardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Peter MacdonaldCardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
John MooreUniversity of New South Wales, Sydney, New South Wales, Australia.
UNSW Sydney · AUVictor Chang Cardiac Research Institute · AUSt Vincent's Hospital Melbourne · AUSt Vincent's Hospital Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.

Indexed as

AmyloidosisImmunoglobulin Light-chain AmyloidosisBortezomibCyclophosphamideDexamethasoneHumansMelphalanRetrospective StudiesBortezomibCyclophosphamideDexamethasoneMelphalanAL amyloidosisbortezomibcardiac amyloidosisheart failuremyeloma

Identifiers

PMID36266066
PMCPMC9828809
OpenAlexW4306933358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.